General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Buy Abbott (ABT) Stock Ahead of Earnings on Coronavirus Testing Push? | news.google.com • |
Paradigm Shift! 4 Of My Favorite Dividend Stocks To Buy Right Now | seekingalpha.com • |
Abbott Laboratories (NYSE:ABT) is Great Lakes Advisors LLC's 7th Largest Position | news.google.com • |
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock | seekingalpha.com • |
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock (NYSE:ABT) | news.google.com • |
Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock (NYSE:ABT) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-17 | 2024-03 | 0.96 | 0.98 | 0.02 | 2.08% |
2024-01-24 | 2023-12 | 1.19 | 1.19 | N/A | N/A |
2023-10-18 | 2023-09 | 1.1 | 1.14 | 0.04 | 3.64% |
2023-07-20 | 2023-06 | 1.04 | 1.08 | 0.04 | 3.85% |
2023-04-19 | 2023-03 | 0.98 | 1.03 | 0.05 | 5.10% |
2023-01-25 | 2022-12 | 0.9 | 1.03 | 0.13 | 14.44% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-18 | Raymond James | Upgrade | Outperform | Outperform |
2023-10-18 | Wells Fargo | Upgrade | Overweight | Overweight |
2023-10-18 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-07-23 | Barclays | Upgrade | Overweight | Overweight |
2023-07-20 | Wolfe Research | Upgrade | Underperform | Peer Perform |
2023-07-20 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-25 | ALPERN ROBERT J | Director | 39.16K | Stock Award(Grant) |
2024-04-25 | BLOUNT SALLY E | Director | 35.02K | Stock Award(Grant) |
2024-05-06 | EARNHARDT LISA D | Officer | 61.46K | Sale |
2024-05-09 | FUNCK ROBERT E. JR. | Officer | 270.61K | Sale |
2024-04-25 | KUMBIER MICHELLE A | Director | 14.08K | Stock Award(Grant) |
2024-04-25 | MCKINSTRY NANCY | Director | 37.09K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 155.74M | 16.98B | 8.97% |
2023-06-29 | Blackrock Inc. | 137.15M | 14.95B | 7.90% |
2023-06-29 | Capital Research Global Investors | 77.23M | 8.42B | 4.45% |
2023-06-29 | State Street Corporation | 74.82M | 8.16B | 4.31% |
2023-06-29 | Capital International Investors | 59.18M | 6.45B | 3.41% |
2023-06-29 | Morgan Stanley | 36.38M | 3.97B | 2.10% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 54.21M | 5.91B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 41.40M | 4.51B | 2.39% |
2023-09-29 | Investment Company Of America | 22.63M | 2.19B | 1.30% |
2023-09-29 | American Mutual Fund Inc | 20.77M | 2.01B | 1.20% |
2023-05-30 | Fidelity 500 Index Fund | 19.51M | 1.99B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 19.19M | 1.97B | 1.11% |
Dividend | Date |
---|---|
0.55 | 2024-04-12 |
0.55 | 2024-01-12 |
0.55 | 2024-01-11 |
0.51 | 2023-10-13 |
0.51 | 2023-10-12 |
0.51 | 2023-07-13 |
Split | Date |
---|---|
10000 : 4798 | 2013-01-02 |
2.0842 : 1 | 2013-01-01 |
10000 : 9356 | 2004-05-03 |
1.06883 : 1 | 2004-05-02 |
2 : 1 | 1998-06-01 |
2 : 1 | 1992-06-01 |
plz check Beautiful 1st screener app With great chart ability : Android: https://dwz1.cc/zkNVfOg
iOS: https://dwz1.cc/uJQCj9R
The Best Stock Screener App Review So Far:
https://dwz1.cc/CjfRfWk
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*
The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
If you have been following $SAVA and their drug PTI-125, you will know that 1 of 2 endpoints was not met recently, sending the stock down, almost 80%. But, I think the exodus was premature. Here is why.
*
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, here is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
*
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, the Casssava IS going to cycle back around to the secondary neuro inflammation endpoint, and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy that the PTI-125 has, with regards to Neuro Inflammation ALONE, makes it A BLOCKBUSTER DRUG!
You now have a claim to a stock like Apple, Ford, or Facebook. In order to keep this claim to your stock, sign up and join Robinhood using my link. https://join.robinhood.com/johns22269
$ABTAbbottsFast COVID Test Poses Safety Issues, Lab Workers Say https://khn.org/MTA4ODU2MA via @khnew
$ABT The U.S. government will nearly double the amount it pays hospitals and medical centers to run Abbott Laboratories’ large-scale coronavirus tests https://www.bloomberg.com/news/articles/2020-04-15/u-s-to-boost-payment-for-abbott-s-covid-19-test-to-increase-use via @bpolitics
$ABTThis latest COVID-19 molecular diagnostic is unique in that it can provide positive test results in as little as five minutes, and negative results within 13 minutes. It is also compact enough to be used in almost any healthcare setting, such as a doctor's office, an urgent care clinic, or hospital emergency departments.